arrow
S

Sandra Plachta-Danielzik

competence network ibd
H指数:26
被引数:2,520

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany

比较抗TNF、乌司奴单抗和 vedolizumab 在克罗恩病中 24 个月的真实世界有效性:来自德国前瞻性 UMBRELLA-IBD 注册研究的合并分析

2026-06-150
OA
Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn's disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment
2025-04-010
PRE
Real-world effectiveness of ustekinumab versus anti-TNF or vedolizumab in ulcerative colitis: induction and 12-month maintenance results from the prospective, observational RUN-UC study

乌司奴单抗相较于抗-TNF或 vedolizumab 在溃疡性结肠炎中的真实世界有效性:来自前瞻性、观察性 RUN-UC 研究的诱导及12个月维持治疗结果

2025-03-270
PRE
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO-ASSIST study)
2024-03-011
OAAI
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naive patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD-study
2023-06-158
OAAI